Part the Cloud Translational Research for Alzheimer's Disease Program: Phase 1 and Phase 2 Clinical Studies

Part the Cloud Translational Research for Alzheimer's Disease Program: Phase 1 and Phase 2 Clinical Studies is sponsored by Alzheimer's Association. This initiative increases research efforts in early-stage human clinical trials (Phase 1 and 2) evaluating novel or repurposed potential medications directed towards Alzheimer's disease and related dementias internationally. In some scenarios, a phase 3 program would also be eligible.

Types of Grants | Alzheimer's Association View and Apply for a Grant View and Apply for a Grant The Alzheimer's Association works to identify and fund a wide range of the most promising grant projects, from basic discovery science to studies addressing social and behavioral aspects of Alzheimer's and related dementias.

Part the Cloud Translational (PTC) Research for Alzheimer’s Disease Program: Phase 1 and Phase 2 Clinical Studies Part the Cloud Translational Research for Alzheimer’s Disease Program: Combination Therapies Program (PTC-CTP) Part the Cloud Translational Research for Alzheimer’s Disease Program: Enable the Molecule for Artificial Intelligence-Discovered Programs (PTC-EM-AI) Funding Program BRING IT: Brain Research & Innovation Network – Grant Initiative of Texas Scientists Pursuing Alzheimer's/Related Dementias Research in Kentucky (SPARK) Program Large-Scale Science Transition Funding Program (LSSTF) Zenith Fellows Award Program (ZENITH) Bridge Funding for Disrupted Neurodegenerative Research Grant Program (BFDN): Powering the Next Generation of Research Alzheimer's Association Funding Program for Global Real-World Data Programs (ALZ-RWD) Alzheimer’s Association World Wide FINGERS Network Funding Program (ALZ WW-FNFP) ISTAART Grant Program for Conferences and Convenings (IGPCC) Active Alzheimer's Association Grants The following funding programs are accepting letters of intent (LOI) or applications at this time.

View the grants' eligibility and deadlines. You can also select a grant for more information. The majority of our grants are open to U.S. and international researchers.

Part the Cloud Translational (PTC) Research for Alzheimer’s Disease Program: Phase 1 and Phase 2 Clinical Studies The Alzheimer's Association is pleased to announce the next offering of the Part the Cloud Translational Research Funding initiative to increase the research efforts in early-stage human clinical trials (Phase 1 and 2) evaluating novel or repurposed potential medications directed towards Alzheimer’s disease and related dementias internationally.

In some scenarios, a phase 3 program would also be eligible. Oct. 20, 2026 – 5 p.

m. ET (Oct. 22 for ISTAART members) Dec.

15, 2026 – 5 p. m. ET (Dec.

17 for ISTAART members) Part the Cloud Translational Research for Alzheimer’s Disease Program: Combination Therapies Program (PTC-CTP) The Alzheimer's Association is pleased to announce a dedicated Part the Cloud Translational Research Funding opportunity to advance combination clinical trials for Alzheimer’s disease and related dementias (AD/ADRD).

This program will support combination strategies that bring together at least two drug approaches, with optional inclusion of additional drug and or behavioral intervention components, to accelerate innovative, biomarker-informed combination therapies into clinical testing. Oct. 20, 2026 – 5 p.

m. ET (Oct. 22 for ISTAART members) Dec.

15, 2026 – 5 p. m. ET (Dec.

17 for ISTAART members) Part the Cloud Translational Research for Alzheimer’s Disease Program: Enable the Molecule for Artificial Intelligence-Discovered Programs (PTC-EM-AI) Funding Program This first-of-its-kind program is designed to bridge the gap between artificial intelligence(AI)-driven therapeutic discovery and the experimental work required to advance AI-generated hits into viable, translational lead candidates for Alzheimer’s disease and related dementias (AD/ADRD).

PTC-EM-AI will identify and invest in therapeutic programs that specifically emerge from artificial intelligence and machine learning (AI/ML) approaches, supporting them at the critical lead-optimization and investigational new drug (IND)-enabling stage. Oct. 20, 2026 – 5 p.

m. ET (Oct. 22 for ISTAART members) Dec.

15, 2026 – 5 p. m. ET (Dec.

17 for ISTAART members) BRING IT: Brain Research & Innovation Network – Grant Initiative of Texas The Brain Research & Innovation Network: Grant Initiative of Texas (BRING IT) is a program of the Rainwater Charitable Foundation in partnership with the Alzheimer’s Association.

BRING IT offers one-year seed grants of up to $100,000 for brain health and dementia research at eligible Texas-based academic institutions and nonprofit organizations. Letter of Intent deadline: Nov. 13, 2026 – 5 p.

m. ET Scientists Pursuing Alzheimer's/Related Dementias Research in Kentucky (SPARK) Program The Scientists Pursuing Alzheimer's/Related Dementias Research in Kentucky (SPARK) program supports early-career investigators based in Kentucky who are working on Alzheimer's and all other dementias. This program is open only to investigators based at an eligible Kentucky organization.

Letter of Intent deadline: Dec. 1, 2026 – 5 p. m.

ET (Dec. 3 for ISTAART members) Application deadline: Feb. 2, 2027 – 5 p.

m. ET (Feb.

4 for ISTAART members) Award notifications: By April 30, 2027 Large-Scale Science Transition Funding Program (LSSTF) The Alzheimer's Association Large-Scale Science Transition Funding Program (LSSTF) supports Alzheimer's disease and related dementias (AD/ADRD) research initiatives that were built on NIH cooperative awards and are moving to their next stage of development, pursuing new funding mechanisms, or adjusting their overall scale.

LSSTF funds the transition itself: sustaining the science and the scientific team through the change. Funds may support scientific continuity (retaining key investigators and study personnel through a funding gap), study continuity (sustaining data collection, biospecimen handling and study operations), and diversification planning (developing co-funding, industry, or philanthropic support).

Pre-submission queries accepted beginning: Six weeks from the date of invitation Within six weeks of review completion Zenith Fellows Award Program (ZENITH) The Zenith Fellows Award provides funding for established investigators who have contributed significantly to AD/ADRD research and to neuroscience advances that inform the understanding of AD/ADRD, and who are likely to make substantial contributions with their proposed work.

Awards are made possible by members of the Alzheimer's Association Zenith Society, who have each committed $1 million in support of the program. Letter of Intent deadline: Dec. 1, 2026, at 5 p.

m. ET (ISTAART members: Dec. 3, 2026, at 5 p.

m. ET) Application deadline: March 30, 2027, at 5 p. m.

ET (ISTAART members: April 1, 2027, at 5 p. m. ET) Award notifications: By Aug.

15, 2027 Bridge Funding for Disrupted Neurodegenerative Research Grant Program (BFDN): Powering the Next Generation of Research U.S. federal government-sponsored research funding has experienced a series of changes that challenges ongoing research initiatives and the future of the U.S. biomedical research enterprise.

This program specifically aims to ensure continuity of career support for early career researchers and researchers who are within seven years of their designation as an Early Stage Investigator (ESI) based on the NIH definition. This program will provide funding for salary and other direct costs for research projects. July 30, 2026; Oct.

30, 2026; Jan.

29, 2027; April 30, 2027 Invited applicants will receive a specific submission deadline (within four weeks of the invitation) and instructions for application submission Within three months of LOI submission Alzheimer's Association Funding Program for Global Real-World Data Programs (ALZ-RWD) Support the infrastructure, data and/or impact of a RWD platform that has, or plans to have, international, national or significant regional reach.

Enhance alignment and collaboration between global platforms, including with ALZ-NET. Have the potential to advance health equity. Pre-submission inquiries are accepted at any time.

Alzheimer’s Association World Wide FINGERS Network Funding Program (ALZ WW-FNFP) Applicants must be a member of the World Wide FINGERS Network. Studies must be equivalent in planning to a Level 2 or Level 1, as described in Kivipelto et al. (2020) Alzheimer’s & Dementia .

Pre-submission inquiries are accepted at any time. ISTAART Grant Program for Conferences and Convenings (IGPCC) The ISTAART Grant Program for Conferences and Convenings (IGPCC) supports Professional Interest Area (PIA)-driven efforts to expand and accelerate research discussion within the International Society to Advance Alzheimer's Research and Treatment (ISTAART).

The program funds new and innovative PIA-led initiatives that increase the impact and reach of ISTAART's PIAs and advance dementia science. Applications are accepted and reviewed on a rolling basis until June 30, 2027. Keep Up With Alzheimer's News and Events Yes, I would like to receive email from the Alzheimer's Association.

* hidden field used for source value to collect web page domain hidden field used for subsource value to collect web page url